Carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma

Bookmark and Share
Published: 9 Dec 2019
Views: 233
Rating:
Save
Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA

Prof Ola Landgren speaks to ecancer at the 2019 ASH meeting in Orlando about the efficacy and safety of carfilzomib, lenalidomide and dexamethasone (KRd) in newly diagnosed multiple myeloma (NDMM) patients.

He explains that the study was a pool analysis, merging 4 single-arm studies. He adds that they were able to compare results between the transplant and non-transplant settings.

Prof Landgren concludes that KRd is an effective and tolerable treatment option for NDMM patients in both settings.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.